The Cooper Companies, Inc. $COO Stock: Inlet Private Wealth LLC Boosts Position

Key Points

• Institutional investors increased their exposure to Cooper Companies: Inlet Private Wealth raised its stake by 571% to 38,920 shares, while several other funds also expanded positions. Institutional investors collectively own 24.39% of the company.
• Cooper Companies authorized a $3 billion share buyback covering up to 22.7% of outstanding shares, and company directors bought shares worth approximately $917,870 during the quarter.
• Analyst sentiment remains cautious: The stock carries a consensus “Hold” rating with an average price target of $68.60, while shares recently traded at $58.97. The company slightly beat quarterly EPS expectations but reported revenue below consensus.

Inlet Private Wealth LLC raised its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 571.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 38,920 shares of the medical device company's stock after purchasing an additional 33,120 shares during the period. Inlet Private Wealth LLC's holdings in Cooper Companies were worth $2,200,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its stake in Cooper Companies by 84.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 192,454 shares of the medical device company's stock valued at $10,879,000 after acquiring an additional 88,216 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Cooper Companies by 834.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 112,677 shares of the medical device company's stock valued at $6,370,000 after acquiring an additional 100,621 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Cooper Companies by 84.0% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 52,747 shares of the medical device company's stock worth $2,982,000 after acquiring an additional 24,084 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Cooper Companies during the third quarter worth about $2,669,000. Finally, Trail Ridge Investment Advisors LLC raised its position in Cooper Companies by 17.1% during the third quarter. Trail Ridge Investment Advisors LLC now owns 12,293 shares of the medical device company's stock worth $695,000 after acquiring an additional 1,793 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Stock Down 0.3%

Shares of NASDAQ COO opened at $58.97 on Thursday. The firm has a market cap of $11.21 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 2.41 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The firm's 50 day moving average price is $62.38 and its 200 day moving average price is $65.86.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the firm posted $0.49 EPS. Cooper Companies's revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, sell-side analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has authorized a share buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

Insider Buying and Selling

In related news, Director Lawrence Kurzius purchased 10,000 shares of the business's stock in a transaction on Monday, September 14th. The shares were bought at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the purchase, the director directly owned 21,099 shares in the company, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Walter Rosebrough, Jr. bought 7,000 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average cost of $54.11 per share, for a total transaction of $378,770.00. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at approximately $919,870. This trade represents a 70.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 34,701 shares of company stock valued at $1,880,039. Insiders own 2.08% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on COO. Wells Fargo & Company set a $61.00 price target on shares of Cooper Companies and gave the company an "equal weight" rating in a report on Thursday, September 10th. Robert W. Baird set a $61.00 target price on Cooper Companies and gave the company a "neutral" rating in a research note on Thursday, September 10th. UBS Group lowered their target price on Cooper Companies from $75.00 to $66.00 and set a "neutral" rating on the stock in a report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the stock a "buy" rating in a research report on Thursday, September 10th. Finally, Bank of America reissued a "neutral" rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $68.60.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women's health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women's health.

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.